MedTrace Logo

Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

NCT01650259 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4876

Last updated 2019-09-18

Study results available
· View outcomes & findings →

Summary

Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as monotherapy in patients with type 2 diabetes mellitus and to assess baseline characteristics of patients with type 2 diabetes mellitus starting Trazenta® Tablets or any other oral antidiabetic monotherapy (naïve or switched from prior therapy of different oral antidiabetic drug).

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

OAD

OAD except Trazenta tablets

DRUG

Trazenta

Linagliptin

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-23
Primary Completion
2017-09-05
Completion
2017-09-14

Countries

  • Japan

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01650259 on ClinicalTrials.gov